Pfizer Inc. (NYSE:PFE) Shares Acquired by Pacer Advisors Inc.

Pacer Advisors Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 5.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 431,232 shares of the biopharmaceutical company's stock after purchasing an additional 20,769 shares during the quarter. Pacer Advisors Inc.'s holdings in Pfizer were worth $12,480,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Olistico Wealth LLC purchased a new position in Pfizer in the second quarter valued at about $25,000. MFA Wealth Advisors LLC acquired a new position in Pfizer during the second quarter worth $29,000. Gladius Capital Management LP boosted its position in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 38,015 shares in the last quarter. Quarry LP acquired a new stake in Pfizer in the second quarter valued at $31,000. Finally, Financial Connections Group Inc. purchased a new position in shares of Pfizer in the second quarter valued at $34,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insiders Place Their Bets

In other news, Director Scott Gottlieb purchased 1,000 shares of the company's stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now directly owns 10,000 shares of the company's stock, valued at approximately $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a "market perform" rating and a $32.00 price objective on the stock. Daiwa America raised shares of Pfizer from a "moderate buy" rating to a "strong-buy" rating in a research note on Wednesday, August 7th. Barclays upped their target price on Pfizer from $30.00 to $32.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Evercore ISI upgraded Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $32.92.

Pfizer Trading Up 2.1 %

PFE stock traded up $0.52 on Friday, hitting $25.65. 41,896,988 shares of the company were exchanged, compared to its average volume of 54,672,200. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $145.36 billion, a price-to-earnings ratio of 34.64, a price-to-earnings-growth ratio of 0.80 and a beta of 0.67. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The business's fifty day moving average is $28.21 and its two-hundred day moving average is $28.57.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business's quarterly revenue was up 31.2% on a year-over-year basis. During the same period last year, the company posted ($0.17) EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.55%. Pfizer's dividend payout ratio is currently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.